GlassScriptPhysician profile
Brandon C Whiteside
NPI 1952367484
$4,670.78
in general payments reported to CMS, 2019-2025
33 companies · $1,151 in 2025
The $1,151 reported for 2025 was more than what 80% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $839 · 2020: $337 · 2021: $539 · 2022: $483 · 2023: $701 · 2024: $621 · 2025: $1,151.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,473.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,473.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $994.16 | 2019-2025 | Clareon, Clareon Panoptix Pro, Tryptyr |
| Bausch & Lomb Americas INC. | $500.69 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $329.84 | 2019-2021 | |
| Carl Zeiss Meditec USA, INC. | $306.64 | 2022-2024 | Iolmaster 700 |
| Allergan, INC. | $300.95 | 2019-2022 | |
| Johnson & Johnson Vision Care, INC. | $251.90 | 2019-2025 | Acuvue |
| Horizon Therapeutics Plc | $217.12 | 2021-2023 | Tepezza |
| Biotissue Holdings INC. | $204.54 | 2020-2025 | |
| Oyster Point Pharma, INC. | $162.50 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Astellas Pharma US INC | $145.82 | 2023-2025 | Izervay |
| Coopervision INC. | $137.46 | 2020-2025 | Myday Contact Lens, Clariti Contact Lens |
| Rayner Intraocular Lenses Limited | $128.22 | 2024-2025 | Omidria |
| Aerie Pharmaceuticals, INC. | $117.93 | 2019-2021 | |
| Johnson & Johnson Surgical Vision, INC. | $110.04 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $104.95 | 2021-2023 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $98.42 | 2021-2025 | Acthar |
| Regeneron Healthcare Solutions, INC. | $76.14 | 2019 | |
| Abbvie INC. | $59.94 | 2023-2025 | Durysta |
| Kala Pharmaceuticals, INC. | $59.20 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $45.88 | 2019 | |
| Ani Pharmaceuticals, INC. | $45.77 | 2022-2023 | Purified Cortrophin Gel |
| Dompe US, INC. | $39.61 | 2019-2025 | Oxervate |
| Harrow Eye, LLC | $34.00 | 2025 | Vevye |
| Merz Pharmaceuticals, LLC | $31.77 | 2022 | |
| Rxsight INC | $29.61 | 2023 | Rxsight Light Adjustable Lens (Rxlal), Rxsight Injector Cartridge, Rxsight Light Delivery Device (Ldd) |
| Biogen, INC. | $27.16 | 2023 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Maculogix, INC. | $18.84 | 2020 | |
| Alcon Research LLC | $18.35 | 2019 | |
| Tearlab Corp | $16.11 | 2024 | Scoutpro Osmolarity System |
| Tarsus Pharmaceuticals, INC. | $13.64 | 2025 | Xdemvy |
| Shire North American Group INC | $12.56 | 2019 | |
| Lumenis, INC | $11.62 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandon Whiteside listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.